Dr. Fracasso is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
VCU Massey Cancer Center
401 College Street
Richmond, VA 23298Phone+1 804-628-0660
Summary
- Board-certified medical oncologist, academic leader, and pharmaceutical executive with significant experience building cancer centers in academic medical centers and developing oncology drugs in biopharmaceutical companies. Expertise in preclinical, translational and clinical development of cellular and immuno-oncology therapies including clinical trial design, regulatory strategies, translational medicine, biomarkers/companion diagnostics, pharmacology, and medical oncology for the delivery of cutting-edge patient care.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1991
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1987
- Yale School of MedicineClass of 1984, MD, PhD, Alpha Omega Alpha
Certifications & Licensure
- VA State Medical License 2007 - 2026
- MO State Medical License 1991 - 2025
- PA State Medical License 2015 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha
- Phi Beta Kappa
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers Start of enrollment: 1998 Mar 01
- Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy Start of enrollment: 2000 Feb 01
- Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer Start of enrollment: 2000 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 225 citationsEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft, Michael Naughton, Kathryn Trinkaus, Mark A. Watson, Lourdes R. Ylagan
The Lancet. Oncology. 2010-05-01 - 9 citationsPhase I study of rubitecan and gemcitabine in patients with advanced malignanciesPaula M. Fracasso, Janet S. Rader, Ramaswamy Govindan, Thomas J. Herzog, Matthew A. Arquette
Annals of Oncology. 2002-11-01 - 54 citationsA phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)Premal H. Thaker, Ritu Salani, W. E. Brady, Heather A. Lankes, David E. Cohn
Annals of Oncology. 2017-03-01
Authored Content
- The Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) Program: Innovative, High-Throughput Clinical Screening of ImmunotherapiesOctober 2018
Press Mentions
- Providing HopeSeptember 30th, 2024
- Paula Fracasso Joins VCU Massey Cancer Center to Lead the Cancer Service LineSeptember 14th, 2022
- Global Cancer Rates in People 50 and Younger on the Rise, Study FindsSeptember 7th, 2022
- Join now to see all
Grant Support
- An Exploratory Study Of UCN-01 And Irinotecan In Advanced Triple Negative BreastNational Cancer Institute2007–2008
- Overcoming Barriers To Early Phase Clinical TrialsNational Cancer Institute2003–2004
- Oral SDZ PSC 833 And Intravenous Paclitaxel In Advanced CancerNational Center For Research Resources1998–1999
- Taxol And SDZ PSC 833 In Patients With Refractory MalignanciesNational Center For Research Resources1997–1999
- Oral SDZ PSC 833 And Intravenous Paclitaxel In Advance CancerNational Center For Research Resources1996
- Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1990–1991
- Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1988
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- Association of American Cancer InstitutesMember
External Links
- Paula Fracassohttp://www.linkedin.com/in/paula-fracasso
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: